LindaRDuskaMD

Obstetrics & Gynecology • Charlottesville, VA

Gynecologic Oncology, Hospice & Palliative Medicine

Professor of Obstetrics & Gynecology, University VA School of Medicine

Join to view full profile

Dr. Duska is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Duska's full profile

Already have an account?

Office
1240 Lee St
Charlottesville, VA 22908
Phone(434) 924-5100
Fax(434) 982-1840
Is this information wrong?

Education & Training

Massachusetts General HospitalFellowship, Gynecological Oncology, 1995 - 1998
Johns Hopkins UniversityResidency, Obstetrics and Gynecology, 1991 - 1995
NYU School of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2019 - 2021
VA State Medical License 2008 - 2022
MA State Medical License 1995 - 2012
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology
American Board of Obstetrics and Gynecology Hospice and Palliative Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Start of enrollment: 2017 Aug 01Linda Duska
Study Comparing AEZS-108/ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) to Doxorubicin as a Second Line Therapy of Endometrial Cancer Start of enrollment: 2013 Apr 01Marijanovic, ..I.,Yachnin, A.,Garcia, A.,Zeimet, A.,Lisyanskaya, A.,Lychko, A.,Vinnytska, A.,Oza, A.M.,Amit, A.,Brown, A.,Oaknin, A.,Rusyn, A.,Pasic, A.,Westermann, A.M.,Casado, A.,Martín, A.G.,Mackowiak-...
A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Start of enrollment: 2012 Sep 01Duska, L.R.
A Phase 0 Pharmacodynamic Study of Dasatinib in Women With Newly Diagnosed Endometrial Cancer Start of enrollment: 2012 Jan 01Duska, L.R.
A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Start of enrollment: 2011 Jan 01Bosscher, J.R.,Buekers, T.E.,Carolla, R.L.,Clarkson, J.E.,Collins, Y.C.,Duska, L.R.,Grendys, E.C.,Mannel, R.S.,Morris, P.C.,Mutch, D.G.,Puls, L.E.,Rojas-Espaillat, L.A.,Rose, P.G.,Service, C.I.,Sharma, S....
A Prospective Trial of COXEN Chemotherapy Prediction Start of enrollment: 2010 Oct 01Duska, L.
A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2010 Apr 01Dizon, D.S.,Duska, L.R.,Mannel, R.S.,Mutch, D.G.,Service, C.I.
A Phase I Study of Carboplatin/Paclitaxel/CTEP Supplied Agent Bevacizumab (NSC #704865, IND #7921) and CTEP Supplied Agent ABT-888 (NSC #737664 IND#77840) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Start of enrollment: 2009 Oct 01Bell-McGuinn, K.,Bell-McGuinn, K.M.,Duska, L.R.,Ghamande, S.A.,Mannel, R.S.,Mutch, D.G.,Rose, P.G.
Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma Start of enrollment: 2006 Feb 01Duska, L.R.,Gross, M.
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Shweta Jain, MD and Leo Nicacio
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Stephanie Lheureux
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer Meghna S Trivedi
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) Francisco Beca, MD, PhD
Join now to see all

Publications & Presentations

PubMed

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular ...
Linda R. Duska, Virginia L. Filiaci, Joan L. Walker, L.L. Holman, Emily K. Hill, Richard G. Moore, Kari L. Ring, Michael L. Pearl, Carolyn Y. Muller, Christina L. Kush...> ;Clinical Cancer Research. 2021 Mar 25
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
J. Gillen, Austin Miller, Katherine M. Bell-McGuinn, Russell J. Schilder, Joan L. Walker, Cara Mathews, Linda R. Duska, Saketh R. Guntupalli, Roisin E. O'Cearbhaill, J...> ;Gynecologic Oncology. 2021 Feb 17
Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success.
J. Stuart Ferriss, Steve Rose, Bunja Rungruang, Renata R. Urban, Ryan J. Spencer, Shitanshu Uppal, Abdulrahman K. Sinno, Linda R. Duska, Christine Walsh> ;Gynecologic Oncology. 2021 Jan 1
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian,...
Linda R. Duska, Carolyn N. Krasner, David M. O'Malley, John L. Hays, Susan C. Modesitt, Cara Mathews, Kathleen N. Moore, Premal H. Thaker, Anthony B. Miller, C. Purdy,...> ;Gynecologic Oncology. 2021 Mar 1
2 citations
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
Linda R. Duska, Jennifer Scalici, Sarah M. Temkin, Julie K. Schwarz, Erin K. Crane, Katherine M. Moxley, Chad A. Hamilton, S. Wethington, Gina R. Petroni, Nikole Varhe...> ;Cancer. 2020 Nov 15
13 citations
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Panagiotis A. Konstantinopoulos, Su Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle, Elizabeth K. Lee, Elise C. Kohn, Linda...> ;Lancet Oncology. 2020 Jun 15
1 citations
Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Megan E Dibbern, Timothy N. J. Bullock, Taylor M Jenkins, Linda R. Duska, Mark H. Stoler, Anne M. Mills> ;The American Journal of Surgical Pathology. 2020 Sep 1
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, f...
Linda R. Duska, Gina R. Petroni, Nikole Varhegyi, Jubilee Brown, Danijela Jelovac, Kathleen N. Moore, William P. McGuire, Christopher J. Darus, Lisa Barroilhet, Angele...> ;Gynecologic Oncology. 2020 Jun 1
1 citations
Are ethnic and racial minority women less likely to participate in clinical trials
Shweta N. Patel, Jeanine N. Staples, Christine Garcia, Lindsay Chatfield, J. Stuart Ferriss, Linda R. Duska> ;Gynecologic Oncology. 2020 May 1
Stuck in the middle: diagnostic and clinical management challenges surrounding CIN2.
Anne M. Mills, Linda R. Duska> ;British Journal of Obstetrics and Gynaecology. 2020 May 1
Validation of the surprise question in gynecologic oncology: A one-question screen to promote palliative care integration and advance care planning.
Lisa A. Rauh, Mackenzie W. Sullivan, Fabian Camacho, Monica J. Janke, Linda R. Duska, Chelsea Chandler, Paniti Sukumvanich, Madeleine Courtney-Brooks, Carolyn Lefkowits> ;Gynecologic Oncology. 2020 Mar 12
3 citations
Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Jacob Curley, Mark R. Conaway, Zachary Chinn, Linda R. Duska, Mark H. Stoler, Anne M. Mills> ;Modern Pathology. 2020 Mar 6
Chemotherapy alone may have equivalent survival as compared to suboptimal surgery in advanced endometrial cancer patients.
Lisa A. Rauh, Jeanine N. Staples, Linda R. Duska> ;Gynecologic oncology reports. 2020 Jan 17
3 citations
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary periton...
Kathleen N. Moore, Austin Miller, Katherine M. Bell-McGuinn, Russell J. Schilder, Joan L. Walker, Roisin E. O'Cearbhaill, Saketh R. Guntupalli, Deborah K. Armstrong, A...> ;Gynecologic Oncology. 2020 Jan 1
The role of pulmonary resection in the management of metastatic gestational trophoblastic neoplasia: Two cases of durable remission following surgery for chemo-resista...
Jeanine N. Staples, Sarah Podwika, Linda R. Duska> ;Gynecologic oncology reports. 2019 Sep 6
The American Society of Clinical Oncology 2019 annual meeting: A review and summary of selected abstracts.
Linda R. Duska, Steven J. Gibson, Steven C. Beall, Bradley J. Monk> ;Gynecologic Oncology. 2019 Jul 12
When prospective randomised trials have unexpected results: where do we go from there?
Linda R. Duska> ;British Journal of Obstetrics and Gynaecology. 2019 Jul 1
1 citations
Quality Initiative to Improve Compliance With Perioperative Anticoagulation.
E. Pelkofski, W. Baker, John C. Rowlingson, Leigh A. Cantrell, Linda R. Duska> ;Journal of Oncology Practice. 2019 Jun 17
9 citations
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Angeles Alvarez Secord, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert Squatrito, Laura J. Havrilesky, Anne C. Gabel, Mark D. Starr, J. Chris Brady,...> ;Gynecologic Oncology. 2019 Jun 1
Interpreting Randomized Clinical Trials in Gynecologic Oncology Surgery: Does One Size Fit All?
Leigh A. Cantrell, Jacobus Pfisterer, John F. Boggess, Linda R. Duska> ;American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2019 May 17
14 citations
Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas
Shuang G. Zhao, William S. Chen, Rajdeep Das, S. Laura Chang, Scott A. Tomlins, Jonathan Chou, David A. Quigley, Ha X. Dang, Travis J. Barnard, Brandon A. Mahal, Ewan ...> ;Clinical Cancer Research. 2019 Apr 15
Urologic Complications Requiring Intervention Following High-dose Pelvic Radiation for Cervical Cancer.
Haerin L. Beller, David E. Rapp, Jacqueline Zillioux, Basil Abdalla, Linda R. Duska, Timothy N. Showalter, Tracey L. Krupski, Theodore I. Cisu, Johnson Yates Congleton...> ;Urology. 2019 Apr 1
11 citations
Endocrine therapy in endometrial cancer: An old dog with new tricks.
Katarzyna J. Jerzak, Linda R. Duska, Helen Mackay> ;Gynecologic Oncology. 2019 Apr 1
1 citations
The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
Allison M. Puechl, James M. Edwards, Anuj Suri, John Nakayama, Sarah M. Bean, Paola A. Gehrig, Erin Saks, Linda R. Duska, Gloria Broadwater, J.A. Ehrisman, Neil S. Hor...> ;Gynecologic Oncology. 2019 Apr 1
3 citations
Cancer Screening and Prevention Highlights in Gynecologic Cancer.
Jeanine N. Staples, Linda R. Duska> ;Obstetrics and Gynecology Clinics of North America. 2019 Mar 1
Join now to see all

Lectures

Surgery Is Critical to a Multidisciplinary Approach to Ovarian Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Dr. Linda R. Duska Appointed Incoming Editor in Chief of ASCO ConnectionJune 22nd, 2016
Clinical Trials Testing COVID-19 Therapies Give UVA Medical Expert HopeDecember 21st, 2020